NASDAQ:RXDX Prometheus Biosciences (RXDX) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$199.60▼$199.9850-Day Range$192.50▼$199.9252-Week Range$23.27▼$199.98Volume1.86 million shsAverage Volume913,102 shsMarket Capitalization$9.56 billionP/E RatioN/ADividend YieldN/APrice Target$162.70 ProfileProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Prometheus Biosciences MarketRank™ ForecastAnalyst RatingHold2.30 Rating ScoreUpside/Downside18.6% Downside$162.70 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.84) to ($4.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.71 out of 5 starsMedical Sector960th out of 962 stocksBiotechnology Industry13th out of 14 stocks 1.2 Analyst's Opinion Consensus RatingPrometheus Biosciences has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 3 buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $162.70, Prometheus Biosciences has a forecasted downside of 18.6% from its current price of $199.92.Amount of Analyst CoveragePrometheus Biosciences has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for RXDX. Previous Next 0.0 Dividend Strength Dividend YieldPrometheus Biosciences does not currently pay a dividend.Dividend GrowthPrometheus Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RXDX. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for RXDX on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prometheus Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.40% of the stock of Prometheus Biosciences is held by insiders.Percentage Held by Institutions92.66% of the stock of Prometheus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Prometheus Biosciences are expected to decrease in the coming year, from ($3.84) to ($4.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prometheus Biosciences is -56.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prometheus Biosciences is -56.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrometheus Biosciences has a P/B Ratio of 12.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Prometheus Biosciences (NASDAQ:RXDX) StockPrometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.Read More RXDX Stock News HeadlinesMay 30, 2023 | seekingalpha.comPrometheus Biosciences: 8.5% IRR And Closing In A MonthMay 28, 2023 | fool.comPrometheus Biosciences (NASDAQ: RXDX)September 24, 2023 | Stansberry Research (Ad)Experts: "NVIDIA Bubble" Could Affect Entire MarketSeveral major analysts are warning that NVIDIA and other tech giants may have gotten “too big to succeed”.May 23, 2023 | msn.comPrometheus Biosciences gains after HSR waiting for sale to Merck expiresMay 23, 2023 | barrons.comSHAREHOLDER ALERT: Weiss Law Investigates Prometheus Biosciences, Inc.May 18, 2023 | finance.yahoo.comWhat Makes Prometheus Biosciences (RXDX) an Attractive Investment Choice?May 12, 2023 | finance.yahoo.comPrometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?May 11, 2023 | msn.comJefferies Downgrades Prometheus Biosciences (RXDX)September 24, 2023 | Stansberry Research (Ad)Experts: "NVIDIA Bubble" Could Affect Entire MarketSeveral major analysts are warning that NVIDIA and other tech giants may have gotten “too big to succeed”.May 11, 2023 | msn.comRBC Capital Maintains Prometheus Biosciences (RXDX) Sector Perform RecommendationMay 9, 2023 | yahoo.comPrometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate ProgressMay 1, 2023 | msn.comAbbvie, Bristol Myers competed with Merck in sale of Prometheus - reportApril 29, 2023 | finance.yahoo.comWith 67% ownership, Prometheus Biosciences, Inc. (NASDAQ:RXDX) boasts of strong institutional backingApril 21, 2023 | finance.yahoo.comPharma Stock Roundup: JNJ Beats on Q1 Earnings, MRK to Buy RXDX & Other UpdatesApril 20, 2023 | finance.yahoo.comWhy Prometheus Biosciences Stock Is Skyrocketing This WeekApril 18, 2023 | markets.businessinsider.comRBC Capital downgrades Prometheus Biosciences (RXDX) to a HoldApril 18, 2023 | finance.yahoo.comPrometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?April 18, 2023 | finance.yahoo.comHow to Tell Biotech’s Likely Winners From LosersApril 17, 2023 | benzinga.comLooking At Prometheus Biosciences's Recent Unusual Options ActivityApril 17, 2023 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Prometheus Biosciences, Inc. (RXDX)April 17, 2023 | finance.yahoo.comPrometheus (RXDX) Stock Surges 70% on Buyout Offer From MerckApril 17, 2023 | barrons.comMerck’s Deal for Prometheus Expected to Generate Billions in Additional SalesApril 17, 2023 | msn.comMerck Acquires Prometheus Biosciences for $10.8 BillionApril 17, 2023 | finance.yahoo.comMerck/Prometheus: Big Pharma must swallow bigger premiumsApril 17, 2023 | finance.yahoo.comHealthcare Is Back. But Is It Here to Stay?April 17, 2023 | investorplace.comRXDX Stock Alert: The $10.8 Billion Reason Prometheus Biosciences Is Surging TodayApril 17, 2023 | investorplace.comWhy Is Prometheus Biosciences (RXDX) Stock Up 70% Today?See More Headlines Receive RXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RXDX Company Calendar Last Earnings5/09/2023Today9/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RXDX CUSIPN/A CIK1557421 Webignyta.com Phone858-422-4300FaxN/AEmployees97Year Founded1995Price Target and Rating Average Stock Price Forecast$162.70 High Stock Price Forecast$200.00 Low Stock Price Forecast$111.00 Forecasted Upside/Downside-18.6%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,750,000.00 Net Margins-3,768.76% Pretax Margin-3,768.76% Return on Equity-33.50% Return on Assets-29.59% Debt Debt-to-Equity Ratio0.04 Current Ratio37.56 Quick Ratio37.56 Sales & Book Value Annual Sales$6.81 million Price / Sales1,403.55 Cash FlowN/A Price / Cash FlowN/A Book Value$16.12 per share Price / Book12.40Miscellaneous Outstanding Shares47,810,000Free Float46,187,000Market Cap$9.56 billion OptionableNot Optionable Beta-0.49 Social Links The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Mark C. McKenna (Age 43)Pres, CEO & Chairman Comp: $1.33MDr. Keith W. Marshall M.B.A. (Age 55)MBA, Ph.D., Chief Financial Officer Comp: $829.45kMr. Mark Stenhouse (Age 56)Chief Operating Officer Comp: $807.4kDr. Olivier Laurent Ph.D. (Age 51)Chief Scientific Officer & Head of R&D Ms. Noel KurdiVP of Investor Relations & CommunicationsMr. Timothy K. Andrews Esq. (Age 44)Gen. Counsel & Sec. Ms. Nori Ebersole (Age 59)Chief People Officer Dr. Allison Luo M.D. (Age 50)Chief Medical Officer Dr. Thierry Dervieux DABCC (Age 55)Ph.d., Pharm.d., Chief Devel. Officer of Diagnostics & Medical Laboratory Director Mr. Chris DoughtyChief Bus. OfficerMore ExecutivesKey CompetitorsBioMarin PharmaceuticalNASDAQ:BMRNHenry ScheinNASDAQ:HSICDaVitaNYSE:DVATeleflexNYSE:TFXQiagenNYSE:QGENView All CompetitorsInsiders & InstitutionsWolverine Trading LLCSold 8,700 shares on 8/23/2023Ownership: 0.000%Walleye Trading LLCSold 1,700 shares on 8/15/2023Ownership: 0.000%Citadel Advisors LLCSold 66,300 shares on 8/15/2023Ownership: 0.000%HAP Trading LLCSold 24,300 shares on 8/11/2023Ownership: 0.000%Citigroup Inc.Sold 25,000 shares on 8/10/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RXDX Stock - Frequently Asked Questions Should I buy or sell Prometheus Biosciences stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last twelve months. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RXDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXDX, but not buy additional shares or sell existing shares. View RXDX analyst ratings or view top-rated stocks. What is Prometheus Biosciences' stock price forecast for 2023? 10 brokers have issued 1 year target prices for Prometheus Biosciences' shares. Their RXDX share price forecasts range from $111.00 to $200.00. On average, they predict the company's stock price to reach $162.70 in the next twelve months. This suggests that the stock has a possible downside of 18.6%. View analysts price targets for RXDX or view top-rated stocks among Wall Street analysts. How were Prometheus Biosciences' earnings last quarter? Prometheus Biosciences, Inc. (NASDAQ:RXDX) posted its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.06. The biopharmaceutical company had revenue of $1.11 million for the quarter, compared to analyst estimates of $0.46 million. Prometheus Biosciences had a negative net margin of 3,768.76% and a negative trailing twelve-month return on equity of 33.50%. The company's quarterly revenue was down 71.8% on a year-over-year basis. What ETF holds Prometheus Biosciences' stock ? Vanguard Russell 2000 Growth ETF holds 27,868 shares of RXDX stock, representing 0.58% of its portfolio. What other stocks do shareholders of Prometheus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD). When did Prometheus Biosciences IPO? (RXDX) raised $126 million in an initial public offering (IPO) on Friday, March 12th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities acted as the underwriters for the IPO. What is Prometheus Biosciences' stock symbol? Prometheus Biosciences trades on the NASDAQ under the ticker symbol "RXDX." Who are Prometheus Biosciences' major shareholders? Prometheus Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Walleye Trading LLC (0.00%), Citadel Advisors LLC (0.00%), HAP Trading LLC (0.00%), Citigroup Inc. (0.00%), Belvedere Trading LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Joseph C Papa, Keith W Marshall, Mark C Mckenna, Mark Stenhouse, Perceptive Advisors Llc and Sinai Intellectual Prop Cedars. View institutional ownership trends. What is Prometheus Biosciences' stock price today? One share of RXDX stock can currently be purchased for approximately $199.92. How much money does Prometheus Biosciences make? Prometheus Biosciences (NASDAQ:RXDX) has a market capitalization of $9.56 billion and generates $6.81 million in revenue each year. The biopharmaceutical company earns $-141,750,000.00 in net income (profit) each year or ($3.52) on an earnings per share basis. Does Prometheus Biosciences have any subsidiaries? The following companies are subsidiares of Prometheus Biosciences: Prometheus Laboratories Inc..Read More How can I contact Prometheus Biosciences? Prometheus Biosciences' mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The official website for the company is ignyta.com. The biopharmaceutical company can be reached via phone at 858-422-4300 or via email at nkurdi@prometheusbiosciences.com. This page (NASDAQ:RXDX) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prometheus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.